These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 3496131)

  • 1. Proteolytic degradation of von Willebrand factor after DDAVP administration in normal individuals.
    Batlle J; Lopez-Fernandez MF; Lopez-Borrasca A; Lopez-Berges C; Dent JA; Berkowitz SD; Ruggeri ZM; Zimmerman TS
    Blood; 1987 Jul; 70(1):173-6. PubMed ID: 3496131
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Response of von Willebrand factor parameters to desmopressin in patients with type 1 and type 2 congenital von Willebrand disease: diagnostic and therapeutic implications.
    Michiels JJ; van de Velde A; van Vliet HH; van der Planken M; Schroyens W; Berneman Z
    Semin Thromb Hemost; 2002 Apr; 28(2):111-32. PubMed ID: 11992235
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Different organization of von Willebrand factor oligomers in type-2A and -2B von Willebrand disease variants: effects of DDAVP infusion and protease inhibitors.
    Casonato A; Pontara E; Bertomoro A; Dannhauser D; Secchiero S; Zaninotto M; Girolami A
    Ann Hematol; 1995 Oct; 71(4):189-94. PubMed ID: 7578526
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Abnormal proteolytic degradation of von Willebrand factor after desmopressin infusion in a new subtype of von Willebrand disease (ID).
    Lopez-Fernandez MF; Gonzalez-Boullosa R; Blanco-Lopez MJ; Perez M; Batlle J
    Am J Hematol; 1991 Mar; 36(3):163-70. PubMed ID: 1996556
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A new variant of von Willebrand's disease (type I Padua): doublet-organized plasma von Willebrand factor oligomers in the presence of all size multimers.
    Casonato A; Pontara E; Dannhäuser D; Bertomoro A; Sartori MT; Girolami A
    Haematologia (Budap); 1994; 26(2):97-109. PubMed ID: 7890268
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multimeric composition of factor VIII/von Willebrand factor following administration of DDAVP: implications for pathophysiology and therapy of von Willebrand's disease subtypes.
    Ruggeri ZM; Mannucci PM; Lombardi R; Federici AB; Zimmerman TS
    Blood; 1982 Jun; 59(6):1272-8. PubMed ID: 6805532
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Laboratory diagnosis of von Willebrand disease type 1/2E (2A subtype IIE), type 1 Vicenza and mild type 1 caused by mutations in the D3, D4, B1-B3 and C1-C2 domains of the von Willebrand factor gene. Role of von Willebrand factor multimers and the von Willebrand factor propeptide/antigen ratio.
    Gadisseur A; Berneman Z; Schroyens W; Michiels JJ
    Acta Haematol; 2009; 121(2-3):128-38. PubMed ID: 19506359
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of desmopressin on von Willebrand factor multimers in Doberman Pinschers with type 1 von Willebrand disease.
    Callan MB; Giger U; Catalfamo JL
    Am J Vet Res; 2005 May; 66(5):861-7. PubMed ID: 15938072
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Survival of von Willebrand factor released following DDAVP in a type 1 von Willebrand disease cohort: influence of glycosylation, proteolysis and gene mutations.
    Millar CM; Riddell AF; Brown SA; Starke R; Mackie I; Bowen DJ; Jenkins PV; van Mourik JA
    Thromb Haemost; 2008 May; 99(5):916-24. PubMed ID: 18449422
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Patients with severe von Willebrand disease are insensitive to the releasing effect of DDAVP: evidence that the DDAVP-induced increase in plasma factor VIII is not secondary to the increase in plasma von Willebrand factor.
    Cattaneo M; Simoni L; Gringeri A; Mannucci PM
    Br J Haematol; 1994 Feb; 86(2):333-7. PubMed ID: 8199023
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A probable double heterozygous type II von Willebrand's disease with increased ristocetin induced platelet aggregation.
    Kinoshita S; Yoshioka K; Kasahara M; Takamiya O
    Am J Hematol; 1992 Jul; 40(3):192-8. PubMed ID: 1609773
    [TBL] [Abstract][Full Text] [Related]  

  • 12. von Willebrand disease "Vicenza" with larger-than-normal (supranormal) von Willebrand factor multimers.
    Mannucci PM; Lombardi R; Castaman G; Dent JA; Lattuada A; Rodeghiero F; Zimmerman TS
    Blood; 1988 Jan; 71(1):65-70. PubMed ID: 3257148
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multimeric analysis of von Willebrand factor before and after desmopressin acetate (DDAVP) administration intravenously and subcutaneously in male beagle dogs.
    Kraus KH; Turrentine MA; Johnson GS
    Am J Vet Res; 1987 Sep; 48(9):1376-9. PubMed ID: 3499101
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Proteolytic processing of von Willebrand factor subunit: heterogeneity in type-IIA von Willebrand disease.
    Batlle J; Lasierra J; Villamor AF; Navarro JL; Pardo A; Campos M; Justiça B; López Fernández MF
    Ann Hematol; 1994 Mar; 68(3):111-5. PubMed ID: 8167176
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Heterogeneity of type I von Willebrand disease: evidence for a subgroup with an abnormal von Willebrand factor.
    Mannucci PM; Lombardi R; Bader R; Vianello L; Federici AB; Solinas S; Mazzucconi MG; Mariani G
    Blood; 1985 Oct; 66(4):796-802. PubMed ID: 3876122
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Acquired von Willebrand disease in multiple myeloma secondary to absorption of von Willebrand factor by plasma cells.
    Richard C; Cuadrado MA; Prieto M; Batlle J; López Fernández MF; Rodriguez Salazar ML; Bello C; Recio M; Santoro T; Gomez Casares MT
    Am J Hematol; 1990 Oct; 35(2):114-7. PubMed ID: 2205095
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical significance of inhibitors in acquired von Willebrand syndrome.
    Mohri H; Motomura S; Kanamori H; Matsuzaki M; Watanabe S; Maruta A; Kodama F; Okubo T
    Blood; 1998 May; 91(10):3623-9. PubMed ID: 9572997
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intravenous DDAVP and factor VIII-von Willebrand factor concentrate for the treatment and prophylaxis of bleedings in patients With von Willebrand disease type 1, 2 and 3.
    Michiels JJ; van Vliet HH; Berneman Z; Gadisseur A; van der Planken M; Schroyens W; van der Velden A; Budde U
    Clin Appl Thromb Hemost; 2007 Jan; 13(1):14-34. PubMed ID: 17164493
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Laboratory diagnosis and molecular classification of von Willebrand disease.
    Gadisseur A; Hermans C; Berneman Z; Schroyens W; Deckmyn H; Michiels JJ
    Acta Haematol; 2009; 121(2-3):71-84. PubMed ID: 19506352
    [TBL] [Abstract][Full Text] [Related]  

  • 20. DDAVP in type IIa von Willebrand's disease.
    Gralnick HR; Williams SB; McKeown LP; Rick ME; Maisonneuve P; Jenneau C; Sultan Y
    Blood; 1986 Feb; 67(2):465-8. PubMed ID: 3080040
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.